TRICALS aims to improve clinical research to finding a cure for ALS. We are conducting a survey among industry partners to assess how the design and operational aspects can be optimized, thereby making clinical trials in ALS more efficient, more cost-effective, and of higher quality.
Your participation is crucial. This 15-minute survey covers essential elements of trial design and operations. The data gathered will be used to develop a new standard for ALS clinical trials. Your insights will significantly contribute to advancing research and improving the future of ALS drug development.
We would greatly appreciate it if you could participate in the survey and share the survey among experts within your organization. Thank you for your invaluable support to develop a highway towards a cure.
Please follow this link to access the survey ⬇️
https://lnkd.in/e3VarMUU
For questions please reach out to: info@tricals.org
Relaterade nyheter
Innovations in ALS clinical trials through the TRICALS Academy
European Commission approves Tofersen as treatment for ALS-SOD1
Amylyx terminates open-label extension of the PHOENIX study
